ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the company’s
ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the companys restatement.
News of the probe came out in ADACs annual 10-K report, filed with the SEC on Jan. 3. In the filing, ADAC stated that it is cooperating with the regulatory agency and that it cannot predict the outcome of the investigation.
In December 1998, ADAC announced that it would restate its financial results for the previous three years, provoking dramatic selling of its stock and shareholder lawsuits (SCAN 1/13/99). ADAC is contesting the suits, which were consolidated in April of last year.
In other ADAC news, the companys HealthCare Information Systems (HCIS) division and Agfa have signed an OEM agreement under which ADAC will distribute Agfas ADC computed radiography systems and Drystar hardcopy printers with its Envoi RIS and PACS systems. The deal is part of ADACs effort to offer a comprehensive RIS/PACS product to its customers, according to the Milpitas, CA-based company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.